Tuesday, March 31, 2020

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA

Biocon#39;s insulin manufacturing facility in Malaysia gets EIR with VAI classification From USFDA In a regulatory filing the company said, Biocon Sdn Bhd, a subsidiary of Biocon Ltd has received the EIR from the USFDA for the Pre-Approval Inspection (PAI) of its insulin manufacturing facility in Malaysia, for Insulin Glargine.

from Moneycontrol Business News https://ift.tt/3azKKTG
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

US equities end lower as valuation concerns creep in

U.S. stocks closed lower on Wednesday as investors took profits amid concerns about high valuations flagged by Fed Chair Powell. The market ...